Frazier Life Sciences Adds Over $630 Million to Evergreen Public Fund

Oversubscribed close brings total committed capital to approximately $1.7 billion for the Frazier Life Sciences Public Fund focused on small- and mid-cap public and later stage private biotech companies.

PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding healthcare investment firm focused on innovative therapeutics, today announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscribed fundraise.

Launched as a dedicated vehicle three years ago, the FLS Public Fund has raised approximately $1.7 billion under the leadership of Albert Cha, Jamie Brush, Jamie Topper and Patrick Heron. The Public Fund is long-only and designed to navigate volatility and liquidity in small- and mid-cap public biotech companies. The Public Fund also has the flexibility to invest in later stage private companies via crossover financings.

Since the Public Fund’s inception, several of the Fund’s largest positions have been acquired including Sierra Oncology (acquired by GSK for $1.9B), Chinook Therapeutics (acquired by Novartis for up to $3.5B) and Alpine Immune Sciences (acquired by Vertex Pharmaceuticals for $4.9B).

“We’re pleased by the strong growth and meaningful milestones we’ve seen from many companies in our portfolio within the Fund’s first three years,” said Albert Cha, Managing Partner at FLS. “We are grateful to have the support of our limited partners, who appreciate the positive impact the therapeutics we invest in can have on patients.”

“Since 2010, FLS companies have received FDA approval for over 50 new therapeutics,” said Jamie Brush, General Partner and Portfolio Manager at FLS. “We look forward to continuing to invest in management teams that we believe drive innovation and deliver transformational treatments to patients in need.”

About Frazier Life Sciences

Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Fund focused on small- and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London.

For more information about Frazier Life Sciences, please visit frazierls.com and follow on LinkedIn.